FDA
The US Food and Drug Administration decides which drugs and gene therapies reach the American market. Posts here follow its rare disease policies and the decisions that affect CMT treatments.
-

·
Faster, Less Predictable: What the FDA’s Turbulent Years Mean for CMT
The FDA has promised faster, more flexible rare disease approvals, but rejections, reversals, leadership churn, and pressure on research funding have made it less predictable. What that means for CMT patients and researchers.
